SXTP

DEL AM - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

S-3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 20

10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement

3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (NCT06207370). The outcome of the interim analysis will be disclosed no later than October 6, 2026. Enrollment will continue in the in

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme diseaseAgreement builds on Company's expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosisCompany continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced tha

DEF 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (NCT06656351), following a review of safety data from the first six patients from baseline through Day 30. The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of tafenoquine (loading dose of 200 mg per day for four days, then 200 mg weekly through Day 90) in patients with severe persiste

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S. WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida State University to commence large-scal

PRE 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestonesMinimum enrollment to support interim analysis expected as soon as early July 2026Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S. WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled in the random

3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.The Company achieved a gross profit of approximately $76 thousand in the first quarter of 2026, compared with a gross profit of approximately $90 thousand in the first quarte